Efficacy and Safety of Topical Diquafosol Ophthalmic Solution for Treatment of Dry Eye

Wu, Di; Chen, Wang Qi; Li, Ryan; Wang, Yan

doi:10.1097/ico.0000000000000429

Cited by 29 publications

(13 citation statements)

References 34 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the TBUT and OSDI results of the present study were similar to those reported previously, there were no significant differences in the Schirmer test or corneal staining scores among the 3 groups. Wu and colleagues reported that unlike TBUT, Schirmer test scores which evaluate aqueous tear production, did not demonstrate consistent improvements after diquafosol treatment in DED patients 17 , as we also report in the current study. Other studies have also shown that Schirmer test scores did not improve after diquafosol treatment of DED patients following cataract surgery 2,13 .…”

Section: Discussionsupporting

confidence: 55%

Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial

Jun

Choi

Lee

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Dry eye disease (DED) after cataract surgery has become a critical concern, and various therapeutic options have been developed. Recently, preservative-free diquafosol ophthalmic solution has been introduced; however, its therapeutic effect on DED after cataract surgery has not been reported. We investigated the efficacy of preservative-free diquafosol in patients with pre-existing DED after cataract surgery. We divided subjects who were diagnosed with DED and scheduled to undergo cataract surgery, into 3 groups (preservative-free diquafosol, group 1; preservative-containing diquafosol, group 2; preservative-free hyaluronate, group 3), and each eye drops was administered 6 times daily after surgery. Tear break up time (TBUT), Ocular Surface Disease Index (OSDI), corneal staining score, lid margin abnormality, and meibum quality improved over time in group 1. Groups 1 and 2 had significantly superior TBUT, meibomian gland dysfunction grade, and meibomian gland expressibility throughout the study period than group 3. Meibum quality of group 1 was significantly better than group 2 at 1 and 3 months after surgery. Preservative-free diquafosol showed better efficacy in treating DED after cataract surgery than preservative-containing diquafosol or preservative-free hyaluronate. Preservative-free diquafosol may serve as a reliable option for the management of patients with pre-existing DED after phacoemulsification.

show abstract

Section: Discussionsupporting

confidence: 55%

Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial

Jun

Choi

Lee

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…According to a systematic review of randomised clinical trials on the efficacy and safety of topical diquafosol for treatment of dry eye by Wu and colleagues, mucin production evaluated using the BUT showed improvement after diquafosol treatment; however, aqueous tear production measured using Schirmer's test did not demonstrate a consistent improvement. Considering the similar results between that study and our study, we could conclude that increased mucin secretion induced by diquafosol plays a major role in increasing tear film stability.…”

Section: Discussionmentioning

confidence: 99%

Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery

Lee

Kim

Choi

et al. 2017

Clinical and Experimental Optometry

View full text Add to dashboard Cite

show abstract

“…Diquafosol is a uridine triphosphate-related compound that stimulates the P2Y2 receptors on the ocular surface (including the conjunctival epithelium, meibomian glands, and goblet cells) and contributes to conjunctival water transfer and mucin secretion [17,18]. Previous reports have concluded that 3% diquafosol sodium eye drops (DQS) were effective in the treatment of dry eye disease [19][20][21][22]. Furthermore, Shigeyasu et al reported that DQS increased the tear meniscus volume and the secretion of sialic acid, which is a mucin-like substance, in the tears in healthy subjects after a single dose [23].…”

Section: Introductionmentioning

confidence: 99%

The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice Treated with Antiglaucoma Eye Medications

et al. 2020

View full text Add to dashboard Cite

Anti-glaucoma eye drop treatment often induces dry eyes and can lead to poor medication adherence. This study aimed to investigate the effects of 3% diquafosol sodium eye drops on tear function and the ocular surface epithelium in Sod1−/− mice after treatment with anti-glaucoma eye drops. The mice were divided into four groups: group 1, control group; group 2, anti-glaucoma eye drop; group 3, anti-glaucoma eye drops followed by a secretagogue eye drop (3% diquafosol); and group 4, simultaneous anti-glaucoma and secretagogue eye drop. Mice underwent assessments of tear quantity, tear film breakup time, and vital staining score. Mice in groups 3 and 4 showed significantly better tear stability and lower corneal staining scores than mice in group 2 after eye drop instillations (p < 0.05). Mice in group 4 showed significantly better tear stability, lower corneal staining scores, and higher goblet cell densities than those in group 1 after eye drop instillations (p < 0.05). The conjunctival epithelium showed stratification and abundance of Muc5AC-positive goblet cells in group 4, whereas thinning with desquamation was observed with a few goblet cells in group 2. Thus, simultaneous administration of 3% diquafosol sodium eye drops with topical anti-glaucoma drops showed favorable effects on tear stability and the corneal epithelium against the ocular surface toxicity inflicted by the anti-glaucoma eye drops.

show abstract

Efficacy and Safety of Topical Diquafosol Ophthalmic Solution for Treatment of Dry Eye

Cited by 29 publications

References 34 publications

Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial

Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial

Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery

The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice Treated with Antiglaucoma Eye Medications

Contact Info

Product

Resources

About